(NaturalNews) A study published in the journal Breast Cancer Research and Treatment has found that women overwhelmingly reject the breast cancer prevention drug tamoxifen even when given a thorough, personalized analysis of its risks and benefits. University of Michigan researchers administered the information about the drug to 632 women and found that only one percent of participants actually ended up taking it.
Originally formulated to prevent recurrences in women who have already had breast
cancer, tamoxifen is now being touted as a
breast cancer prevention drug.
The women who participated in the study were given detailed
information about how the drug would work for them based on a number of personalized factors. These included medical and family history, age, and race. After completion, only 29 percent of women said they would
research the drug further. A mere six percent said they were likely to actually take tamoxifen.
Following the study, of the 29 percent who said they would seek out more information about tamoxifen, only six percent actually did. Among those who said they were likely to take it, a measly one percent followed through.
Eighty-percent of the
women who participated in the study indicated that they were most concerned about the side effects of the
drug, which include sexual problems, hot flashes, blood clots, cataracts, and endometrial cancer. Despite concern among some that women are not taking the drug because they don't know about it, Dr. Peter Ubel from the University of Michigan noted that the real reason women are not taking tamoxifen is because of the many dangers associated with it.
Comments by Mike Adams, the Health Ranger
This is a fascinating study because it shows that
when women are properly informed about the dangers of cancer drugs, they almost universally reject them.
This is why the cancer industry works so hard to keep women ignorant by distancing them from accurate information about the dangers of chemotherapy, radiation, surgery and anti-cancer
drugs. The more women know about these things, the more they reject conventional cancer treatments altogether (and the more they seek out alternative therapies).
Alternative (natural) therapies are non-toxic, safe, affordable and highly effective at both preventing and treating cancer.
Sources for this story include:http://www2.med.umich.edu/prmc/media/newsroom/details.cfm?ID=1393
About the author: Mike Adams is an award-winning journalist and holistic nutritionist with a passion for teaching people how to improve their health He is a prolific writer and has published thousands of articles, interviews, reports and consumer guides, impacting the lives of millions of readers around the world who are experiencing phenomenal health benefits from reading his articles. Adams is an honest, independent journalist and accepts no money or commissions on the third-party products he writes about or the companies he promotes. In 2010, Adams launched NaturalNews.TV, a natural health video site featuring videos on holistic health and green living. He also launched an online retailer of environmentally-friendly products (BetterLifeGoods.com) and uses a portion of its profits to help fund non-profit endeavors. He's also a successful software entrepreneur, having founded a well known email marketing software company whose technology currently powers the NaturalNews email newsletters. Adams is currently the executive director of the Consumer Wellness Center, a 501(c)3 non-profit, and regularly pursues cycling, nature photography, Capoeira and Pilates. He's also author of numerous health books published by Truth Publishing and is the creator of several consumer-oriented grassroots campaigns, including the Spam. Don't Buy It! campaign, and the free downloadable Honest Food Guide. He also created the free reference sites HerbReference.com and HealingFoodReference.com. Adams believes in free speech, free access to nutritional supplements and the ending of corporate control over medicines, genes and seeds.
Have comments on this article? Post them here:
people have commented on this article.
Tuesday, December 22, 2009
Email this article to a friend
Share this article on: 
Now Available from 
